AzTrials
AzTrials

Postmenopausal WomenNCT06042673

Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers

A study testing Pomegranate seed oil and Mixed vegetable oil in people with Postmenopausal Women, run by University of Reading at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Dietary fat plays a crucial role as a modifiable risk factor influencing both non-fasting lipaemia and vascular reactivity. Notably, the intake of dietary saturated fatty acids (SFAs) has been associated with adverse effects on blood lipid profiles, whereas increased consumption of unsaturated fatty acids (UFAs) has… Read more about this study

Who is it for?
Ages Up to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Postmenopausal Women
What is being tested?
Pomegranate seed oil and Mixed vegetable oil
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15 participants
Where
1 siteUnited Kingdom
Study dates
6 Jul 2023to 28 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 65 years
  • Women only
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Postmenopausal women who have been postmenopausal for at least 12 months.
  • Aged 65 and under years
  • Serum TAG < 2.3 mmol/l
  • Body mass index (BMI) between 18-35 kg/m2
  • Fasting total cholesterol < 7.5 mmol/l
  • Fasting glucose concentration <7 mmol/L

Who cannot join

  • Smokers
  • Medical history of myocardial infarction or stroke in the past 12 months
  • Diabetes (defined as fasting glucose > 7.0 mmol/l) or other endocrine disorders
  • Kidney, liver, pancreas or gastrointestinal disorder
  • Hypertension (blood pressure > 140/90 mmHg), cancer, medication for hyperlipidaemia (e.g. statins), hypertension or, inflammation
  • Anaemia (<115 g/L haemoglobin)
Show all 11Show fewer
  • Taking any dietary supplements known to influence lipids/gut microbiota (e.g. plant stanols, fish oil, phytochemicals, natural laxatives, probiotics and prebiotics)
  • Drinking in excess of 14 units of alcohol per week
  • Planning on a weight-reducing regime
  • Parallel participation in another dietary intervention study
  • Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study

Trial locations and contacts

1 site in 1 country.

Jeremy Spencer, BSc, PhD contact

+44(0)1183788724

j.p.e.spencer@reading.ac.uk

United Kingdom1 site, 1 recruiting
  • Department of Food and Nutritional Sciences, University of Reading

    Reading, RG6 6AP

    Jeremy Spencer, BSc, PhD, j.p.e.spencer@reading.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers in Postmenopausal Women.

Dietary fat plays a crucial role as a modifiable risk factor influencing both non-fasting lipaemia and vascular reactivity. Notably, the intake of dietary saturated fatty acids (SFAs) has been associated with adverse effects on blood lipid profiles, whereas increased consumption of unsaturated fatty acids (UFAs) has shown potential to improve lipid health. Pomegranate seed oil (PSO) stands out due to its high content of conjugated α-linolenic acids (CLnAs). However, research comparing the impact of these fatty acids on postprandial vascular function, particularly in postmenopausal women, remains limited. A cross-over, single-blind, randomised acute postprandial study will be conducted in 15 healthy postmenopausal women. Participants will be assigned to consume the test meals either a placebo (50 g of mixed fat; 4:0.5:0.5 palm oil: rapeseed oil: safflower oil) or PSO (40 g of mixed fat and 10g of PSO) in random order on 2 separate occasions, with 4-6 weeks between each study visit. The anthropometric, blood pressure, and arterial stiffness, will be taken for each study visit. Blood samples will be collected for the measurement of fasting lipids, glucose, insulin, inflammatory markers, and whole blood culture. The findings from this study will contribute to the evidence base on how consuming meals rich in PSO influence the level of blood lipids as well as other biomarkers for cardiovascular disease.

Being tested
Pomegranate seed oil, Mixed vegetable oil

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pomegranate seed oilDietary supplement

    10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast

  • Mixed vegetable oilDietary supplement

    50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast

Study groups in NCT06042673
Study groupRoleWhat they receive
Pomegranate seed oilExperimentalParticipants will be asked to consume breakfast (0 minute) containing pomegranate seed oil
Receives: Dietary Supplement: Pomegranate seed oil
mixed vegetable oilPlacebo comparatorParticipants will be asked to consume breakfast (0 minute) containing mixed vegetable oil
Receives: Dietary Supplement: Mixed vegetable oil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in postprandial triacylglycerol

    Triacylglycerol

    Measured: Acute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutes

Secondary outcomes (5)
  1. Fasting blood lipids

    Total cholesterol, high density lipoprotein cholesterol

    Measured: Acute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutes

  2. Change from baseline in postprandial insulin

    Insulin

    Measured: Acute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutes

  3. Change from baseline in postprandial endothelial activation

    E-selectin, P-selectin, vascular cell adhesion molecule 1, intercellular adhesion molecule-1

    Measured: Acute study: taken at 0 (baseline),180, 300 and 420 minutes

  4. Change from baseline in postprandial blood pressure

    Systolic and diastolic blood pressure Systolic and diastolic blood pressure Systolic and diastolic blood pressure Systolic and diastolic blood pressure

    Measured: Acute study: taken at 0 (baseline), 120, 240, 360 and 480 minutes

  5. Change from baseline endothelial microvascular function

    Laser Doppler imaging (LDI) with iontophoresis

    Measured: Acute study: taken at 0 (baseline),180, 300 and 420 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2023
  2. Study start6 Jul 2023
  3. Primary completion20 Feb 2024
  4. Study completion28 Jul 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06042673
Sponsor's protocol ID
UREC 22/11
Status last verified
Apr 2024
First submitted
5 Sep 2023
Last updated
29 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Almoraie MM, Spencer JP, Wagstaff C, Jackson KG. Acute Effects of a High-Fat Meal Enriched with Pomegranate Seed Oil on Postprandial Lipemia and Endothelial Function in Postmenopausal Women: a Randomized Controlled Crossover Trial. J Nutr. 2026 Mar;156(3):101374. doi: 10.1016/j.tjnut.2026.101374. Epub 2026 Jan 22.

    PubMed 41580088

Questions about this trial

What is this clinical trial studying?

A study testing Pomegranate seed oil and Mixed vegetable oil in people with Postmenopausal Women, run by University of Reading at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jeremy Spencer, BSc, PhD (+44(0)1183788724, j.p.e.spencer@reading.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in postprandial triacylglycerol (time frame: Acute study: taken at 0 (baseline), 30, 60, 90, 120, 180, 240, 300, 360, 420, 480 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06042673, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in